Heart Care Info - Heart Disease Prevention & Treatment

Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: Clinical and economic outcomes

WE Uber, JM Toole, MR Stroud, JS Haney... - ... and Cardiovascular ..., 2011 - AATS/WTSAObjective: Refractory bleeding after complex cardiovascular surgery often leads to increased length of stay, cost, morbidity, and mortality. Recombinant activated factor VII administered in the intensive care unit can reduce bleeding, transfusion, and surgical re-exploration. We ...

a Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC

b Department of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC

c Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC

Received for publication April 30, 2010; revisions received November 12, 2010; accepted for publication February 25, 2011.

Objective: Refractory bleeding after complex cardiovascular surgery often leads to increased length of stay, cost, morbidity, and mortality. Recombinant activated factor VII administered in the intensive care unit can reduce bleeding, transfusion, and surgical re-exploration. We retrospectively compared factor VII administration in the intensive care unit with reoperation for refractory bleeding after complex cardiovascular surgery.

Methods: From 1501 patients who underwent cardiovascular procedures between December 2003 and September 2007, 415 high-risk patients were identified. From this cohort, 24 patients were divided into 2 groups based on whether they either received factor VII in the intensive care unit (n = 12) or underwent reoperation (n = 12) for refractory bleeding. Preoperative and postoperative data were collected to compare efficacy, safety, and economic outcomes.

Results: In-hospital survival for both groups was 100%. Factor VII was comparable with reoperation in achieving hemostasis, with both groups demonstrating decreases in chest tube output and need for blood products. Freedom from reoperation was achieved in 75% of patients receiving factor VII, whereas reoperation was effective in achieving hemostasis alone in 83.3% of patients. Prothrombin time, international normalized ratio, and median operating room time were significantly less (P < .05) in patients who received factor VII. Both groups had no statistically significant differences in other efficacy, safety, or economic outcomes.

Conclusions: Factor VII administration in the intensive care unit appears comparable with reoperation for refractory bleeding after complex cardiovascular surgical procedures and might represent an alternative to reoperation in selected patients. Future prospective, randomized controlled trials might further define its role.

Related Article

The hazard of comparing apples and oranges: The proper indication for the use of recombinant activated clotting factor VII in cardiac surgery Vincenzo Tarzia, Tomaso Bottio, Edward Buratto, Luca Spiezia, Paolo Simioni, and Gino Gerosa J. Thorac. Cardiovasc. Surg. 2011 142: 1588-1589. [Extract] [Full Text] [PDF]